Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials.
Expert Opin Investig Drugs
; 30(11): 1109-1124, 2021 Nov.
Article
en En
| MEDLINE
| ID: mdl-34842481
ABSTRACT
INTRODUCTION:
Ankylosing spondylitis (AS) is a chronic inflammatory disease whose main hallmark is involvement of the axial skeleton. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line treatment; however, their use is limited because of side effects. Tumor necrosis factor inhibitors (TNFi) are a safe and effective therapy, and they have been approved for the management of AS. AREAS COVERED This is a review of the efficacy of TNFi in disease modification in AS. It is focused on results from early-phase clinical trials; however, it also discusses the most relevant findings in order to optimize anti-TNF treatment. A literature search was done using PubMed, Medline, Embase, Google Scholar, and Cochrane library, looking for scientific publications from inception to August 2021. Further information was retrieved from ClinicalTrial.gov and Clinicaltrialsregister.eu. EXPERT OPINION TNFi have demonstrated short- and long-term improvements in all aspects of disease activity, as well as physical function in patients with AS. They have drastically revolutionized the management of the disease; and even though new drugs have become available in the market, TNFi has not been displaced for the treatment of AS, and still constitute the best alternative when NSAIDs are no-longer an option.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Espondilitis Anquilosante
/
Antiinflamatorios no Esteroideos
/
Inhibidores del Factor de Necrosis Tumoral
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Investig Drugs
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2021
Tipo del documento:
Article
País de afiliación:
Reino Unido